The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.
Clara LemosVolker K SchulzeSimon J BaumgartEkaterina NevedomskayaTobias HeinrichJulien LefrancBenjamin BaderClara D ChristHans BriemLara P KuhnkeSimon J HoltonUlf BömerPhilip LienauFranz von NussbaumCarl F NisingMarcus BauserAndrea HägebarthDominik MumbergBernard HaendlerPublished in: Cellular oncology (Dordrecht) (2021)
The availability of the potent inhibitor BAY-3827 will contribute to a better understanding of the role of AMPK signaling in cancer, especially in prostate cancer.